Event Date: 06/14/2020
On May 28,2020 the FDA approved the first drug to image Tau pathology in patients being evaluated for Alzheimer’s Disease. This marks a significant advancement toward making more definitive assessments when using brain imaging. Tauvid (flortaucipir F18) was approved for intravenous injection to help “tau pathology” using positron emission tomography (PET) imaging to estimate the density and distribution of aggregated tau neurofibrillary tangles, a primary marker of Alzheimer’s Disease. After Tauvid is administered, it binds to sites in the brain associated with this tau protein misfolding making them more visible on the PET scan. The Alzheimer’s Helpline is accessible 24/7 via 800.272.3900 and staffed by masters-level clinicians to assist with crisis situations, decision-making, and disease information. You can find virtual dementia caregiver resources online at alz.org/covid19help. Tools and supports are also available in Spanish.
Post Date: June 8, 2020